Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective

Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective

Objectives: The clinical benefit of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus twice-daily budesonide/formoterol (BUD/FOR) for patients with symptomatic chronic obstructive pulmonary disease (COPD) was demonstrated in a clinical trial setting (FULFIL [NCT02345161]). T...

Full description

Bibliographic Details
Main Authors: Melanie Schroeder, Dhvani Shah, Nancy Risebrough, Alan Martin, Shiyuan Zhang, Kerigo Ndirangu, Andrew Briggs, Afisi S. Ismaila
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Respiratory Medicine: X
Online Access:http://www.sciencedirect.com/science/article/pii/S2590143519300089

Internet

http://www.sciencedirect.com/science/article/pii/S2590143519300089

Similar Items